Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) — Cash Flow-to-Debt Ratio
Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) has a Cash Flow-to-Debt Ratio of 0.08x as of September 2025, meaning its operating cash flow of CN¥11.57 Million could theoretically repay 0% of its total liabilities (CN¥142.19 Million) in one year. See 301211 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Cash Flow-to-Debt Ratio (2017–2025)
Historical debt coverage capacity for Hubei Biocause Heilen Pharmaceutical Co. Ltd. across 9 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Hubei Biocause Heilen Pharmaceutical Co..
Annual Cash Flow-to-Debt Ratio for Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2017–2025)
Year-by-year debt coverage analysis for Hubei Biocause Heilen Pharmaceutical Co. Ltd.. Check earnings quality score of Hubei Biocause Heilen Pharmaceutical Co. to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.06x | CN¥7.55 Million | CN¥128.65 Million | ▼ -89.1% |
| 2024 | 0.54x | CN¥96.07 Million | CN¥178.97 Million | ▼ -25.6% |
| 2023 | 0.72x | CN¥137.06 Million | CN¥189.89 Million | ▼ -36.3% |
| 2022 | 1.13x | CN¥250.79 Million | CN¥221.22 Million | ▼ -1.7% |
| 2021 | 1.15x | CN¥123.98 Million | CN¥107.53 Million | ▼ -2.5% |
| 2020 | 1.18x | CN¥121.67 Million | CN¥102.85 Million | ▼ -18.2% |
| 2019 | 1.45x | CN¥372.33 Million | CN¥257.31 Million | ▲ +356.5% |
| 2018 | 0.32x | CN¥76.18 Million | CN¥240.36 Million | ▲ +210.1% |
| 2017 | -0.29x | CN¥-65.44 Million | CN¥227.25 Million | — |